A new radiotracer, 18F-FDG PET/CT, has been shown to be highly effective in detecting rare and aggressive kidney cancer, renal medullary carcinoma (RMC). The tracer identified lesions in 98% of RMC patients and led to a change in treatment plan for 21% of patients with active disease, highlighting its potential to improve patient care.
Researchers at Nagoya University have identified giant-nucleus cells as precancerous markers in the kidneys, which emerge in response to iron toxicity and BRCA1 mutations. These cells exhibit cancer-related gene activity and can signal early cancer development in surrounding tissue, with distinct biological profiles in BRCA1-mutant rats.
Researchers at MSK have identified a protein called integrin alpha-5 as a key driver of lung metastasis across several cancer types. A new three-drug combination that includes epcoritamab, rituximab, and lenalidomide is effective in almost all patients newly diagnosed with follicular lymphoma, offering a potential alternative to chemot...
A new theranostic pair, 68Ga/177Lu-NYM096, shows excellent tumor uptake in clear cell renal cell carcinoma lesions and demonstrates early evidence of tumor response in patients. The radiotracer can identify tumors and deliver targeted radiotherapy, mitigating toxicity issues common with treatment.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
A new clinical study demonstrates casdatifan's effectiveness in treating advanced kidney cancer with durable tumor responses and a manageable safety profile. The treatment targets HIF-2 biology and biomarker changes, supporting precision medicine approaches.
A rare benign kidney tumor, renal oncocytoma, is diagnosed through biopsy and histopathology, guiding individualized treatment decisions. Minimally invasive approaches like percutaneous cryoablation provide effective disease control while preserving kidney function.
Casdatifan, a next-generation HIF-2α inhibitor, demonstrates effectiveness in treating metastatic clear cell renal cell carcinoma with manageable side effects and promising signs of efficacy.
Researchers discover that kidney cancer cells lacking the tumor suppressor gene SETD2 become highly dependent on protein BCL-xL for survival. By targeting this dependency, they can selectively eliminate SETD2-deficient cancer cells, offering a potential new therapeutic strategy for patients with aggressive subset of kidney cancers.
The FDA has approved pembrolizumab and belzutifan as an adjuvant treatment for adult patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy. The combination resulted in a 28% decrease in risk of recurrence, metastasis or death, and 81% of participants remained cancer-free after 24 months.
Researchers at MSK discovered that tumors with low levels of NF2, a tumor suppressor gene, are less likely to respond to immunotherapy. They also found that combinations of VEGFR-TKIs and immunotherapies can be effective but have limited long-term benefits due to paradoxical effects of hypoxia on treatment response.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
The S2419 BioFront study aims to enroll over 700 patients with advanced renal cell carcinoma and test the safety and efficacy of a CBM588 capsule as part of an immunotherapy-based treatment. The trial seeks to improve outcomes for patients by leveraging the gut microbiome.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Researchers found a clear connection between oral health and kidney health, with immune dysregulation and systemic inflammation driving the relationship. The study highlights the need for physicians to integrate oral and renal health into clinical care systems.
Cryotherapy has been shown to be an effective and safe treatment option for small kidney tumors, destroying cancer cells while preserving kidney function. The procedure is less invasive than surgery and can be repeated several times, making it a promising alternative for patients with early-stage kidney cancer.
A phase 3 study found that combining belzutifan with pembrolizumab after surgery significantly improved disease-free survival for high-risk kidney cancer patients. The regimen reduced recurrence by 28% and kept 81% of participants cancer-free.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
A new study by University of Texas M. D. Anderson Cancer Center researchers has identified a myeloid mimicry pathway that drives tumor hyper progression following immunotherapy in renal medullary carcinoma, highlighting specific targets for overcoming treatment resistance.
Researchers found that interferon-gamma signaling in myeloid cells corresponds with resistance to immunotherapy in advanced renal cell carcinoma. This study could help identify biomarkers for predicting response to immunotherapy and inform the development of new therapies.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
A comprehensive molecular analysis of renal medullary carcinoma identified overexpression of TROP2 and the Hippo pathway in patients. The study found sacituzumab govitecan to result in partial responses and stable disease in heavily pretreated RMC patients.
A study found that further testing in renal cell carcinoma with an overexpression of gene TRIM63 could uncover a mutation otherwise undetected, leading to more treatment options. In cases where tumors were positive for TRIM63 on a biomarker level but FISH negative, 70% ended up having MiTF gene rearrangement.
A randomized trial found that patients with metastatic clear-cell renal carcinoma lived longer without disease progression when treated with lenvatinib and everolimus compared to cabozantinib. The study suggests that lenvatinib plus everolimus may offer a more meaningful benefit as second-line treatment for these patients.
Dana-Farber researchers present promising phase 3 trial results for breast, lung, and bladder cancers, including improved quality of life for metastatic breast cancer patients. The trials also explore new approaches to kidney cancer treatment and real-world data analysis for metastatic breast cancer.
Researchers at CNIO have created a 'human repairome', a catalogue of 20,000 DNA 'scars' that reveal how genes affect DNA repair. This information can help determine the best treatment for each cancer type and overcome resistance to therapy.
A study published in European Urology predicts a doubling of kidney cancer cases worldwide over the next 25 years. Modifiable risk factors such as obesity, smoking, lack of exercise, diabetes, and hypertension are expected to drive this rise.
Dr. Eggener brings extensive expertise in prostate and testicular cancer detection, diagnosis, and treatment to UCLA Health. He aims to improve prostate cancer detection and treatment through research.
Researchers discovered PRMT5 regulates ACSL4 methylation, which promotes ferroptosis in renal cell carcinoma. Inhibiting PRMT5 increases ferroptosis and enhances immunotherapeutic treatment efficacy.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
Researchers used AI models with integrated clinical and claims data to predict chronic kidney disease (CKD) progression to end-stage renal disease (ESRD). The study found that the models outperformed single data source models and reduced racial bias. The findings can inform likelihood and management of CKD, supporting targeted interven...
Researchers have developed AlloCAR70-NKT, an innovative cell therapy harnessing the immune system to fight cancer. The therapy demonstrates a multi-pronged attack against kidney cancer, directly killing cells and disrupting the tumor's microenvironment.
A study published in Nature Medicine reports final results of a Phase 3 trial showing pembrolizumab plus axitinib offers longer overall and progression-free survival compared to sunitinib for advanced kidney cancer patients. The treatment combination has been linked to higher objective response rates.
Researchers identified key factors behind a successful immunotherapy response in a young patient with rhabdoid tumour. The study highlights the potential of sequencing technologies to track immune cell profiles and develops personalized cell therapies.
Chromophobe renal cell carcinoma (ChRCC) has fewer T-cells and poorer response rates to traditional immune therapies compared to other kidney cancers. Researchers identified unique immune evasion mechanisms in ChRCC and proposed therapeutic strategies to steer cancer-specific immune cells into the tumor.
QUT researchers create novel composite traits from UK Biobank data, identifying 50,000 biomarkers that outperform eGFR in detecting CKD. Their approach uncovers genetic signals missed by traditional methods.
A study published in Genome Medicine has identified the underlying predisposition for Wilms' tumors, highlighting the role of mutations in tumor suppressor genes like WT1. The research also reveals a significant proportion of childhood kidney tumors have a hereditary component, with implications for genetic counseling and monitoring.
Christopher Kane's appointment as ABU president reflects his commitment to excellence in patient care, groundbreaking research, and physician mentorship. As president, he will refine certification protocols and enhance the urologist experience.
A study led by Johns Hopkins Medicine scientists found that rearranged genes in a rare type of kidney cancer form liquid droplets that turn on cancer-promoting genes. By disrupting these droplets, researchers may develop new therapies for this currently untreatable cancer.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A multicenter cohort study found that IV magnesium administration may reduce the incidence of cisplatin-associated kidney damage, with a 20% lower adjusted odds of developing kidney damage compared to those who did not receive IV magnesium.
W. Kimryn Rathmell, former NCI director, joins Ohio State as CEO of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. She will lead the clinical and research excellence of Ohio State's cancer program, including operational oversight of both hospitals.
Researchers are exploring the use of immunotherapy drugs and a tumor-busting 'oncolytic' virus to tackle high-grade neuroendocrine tumors. A new clinical trial, led by Dr. Aman Chauhan, aims to unlock the mysteries of renal cell carcinoma through detailed laboratory and clinical studies.
Researchers estimate that one in 2,710 to one in 4,190 individuals carries a variant of the FLCN gene linked to Birt-Hogg-Dubé syndrome. This condition increases the risk of kidney cancer, which is significantly lower in carriers than previously thought.
New research suggests that maintaining a healthy weight throughout life and losing weight later in life may reduce the risk of kidney cancer. Higher BMI at various ages across adulthood was associated with increased risks of developing different types of kidney cancer, including renal cell carcinoma, papillary RCC, and chromophobe RCC.
A simple urine test has shown promising results in detecting early-stage kidney cancer recurrence, with a high sensitivity and specificity rate. The GAGome test can accurately identify patients at risk of recurrence, potentially reducing the need for invasive scans and enabling faster treatment access.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.
Researchers at Dana-Farber Cancer Institute present studies on novel treatments for prostate, kidney, and bladder cancers. The team introduces a novel HIF-2α inhibitor called casdatifan, which shows promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.
A new technique using optical coherence tomography (OCT) probe aims to improve kidney biopsy imaging, reducing failed surgeries and improving patient outcomes. The technology could also help identify tumor types and reduce cases of renal hemorrhage.
A new study has mapped genetic differences across children with Wilms tumour, a type of childhood kidney cancer, to understand how it develops and responds to treatment. The research suggests that inherited genetic changes predetermine tumour development, growth, and response to treatments.
A phase 2 study found that the combination of belzutifan and cabozantinib produced a confirmed objective response rate of 70% among patients with advanced clear-cell renal cell carcinoma. The treatment was well-tolerated, with manageable serious adverse events.
Researchers have discovered a correlation between patterns in cells of tumors and patient outcomes in clear cell renal cell carcinoma (ccRCC). The study found two different patterns of nuclear speckles that may guide personalized therapies. Further research is needed to understand the implications of this discovery.
A new study by Katherine Alexander and Shelley Berger has found a possible source of variability in cancer treatment response in clear cell renal cell carcinoma (ccRCC). The researchers identified two distinct patterns of nuclear speckles in kidney tumors, which may correlate with patient outcomes.
A researcher at the Medical University of South Carolina is developing a new approach to boost the immune system's ability to detect and kill kidney tumors. By targeting mitochondrial DNA, he aims to reactivate the immune system to recognize and target cancer cells more effectively.
Researchers aim to improve treatment response in patients with clear cell renal cell carcinoma by reprogramming tumor cells into immune cells that recognize and kill cancer cells. This approach combines checkpoint inhibitors to enhance the immune response.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.